There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start by year-end 2025 Sept. 08, 2025 -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the Company received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1b cha

Sept. 05, 2025 -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract titled “Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS” was selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025, in Barcelona, Spain.

Sept. 03, 2025 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insig

Sept. 02, 2025 -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor types. OBI-902 is the first OBI- developed ADC that uses our proprietary Glycan ADC enabling technology. OBI plans to enroll patients with advanced solid tumors with the objective of verifying the safety, pharmacokinet

Aug. 28, 2025 -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. AAVantgarde will also be presenting at the Ophthalmology Futures Forum (OFF) and EURetina Innovation Spotlight (EIS) events on the 3rd S

Aug. 26, 2025 -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company’s decision to pursue an artificial intelligence-led drug repurposing strategy for its portfolio. CDT, in collaboration with Sarborg, has carried out an in-depth analysis of AZD1656, uti

Aug. 22, 2025 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced its participation in the 22nd Urological Association of Asia Congress which was held in conjunction with the 47th Ann

First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers The Company recently announced the results from its Phase II placebo-controlled clinical trial of potravitug which showed biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients Plans are underway to progress potravitug into Phase III development with the potential to transform the treatment landscape for kidney trans

- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation Aug. 19, 2025 -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2115 for the treatment of osteogenesis imperfecta (OI) will be presented at the American Society for Bone and

Aug. 18, 2025 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for DTX401 AAV gene therapy as a treatment for Glycogen Storage Disease Type Ia (GSDIa). The company has submitted the non-clinical and clinical modules to the FDA and plans to complete the full BLA including submission of the chemistry, manufacturing and controls (CMC) modul